QOP
KROS icon

Quinn Opportunity Partners’s Keros Therapeutics KROS Stock Holding History

Quinn Opportunity Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,000
Closed -$255K – 392
2025
Q1 		$255K Buy
+25,000
New +$290K 0.02% 318

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quinn Opportunity Partners's KROS Position: Q2 2025 in Review

Quinn Opportunity Partners sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 25,000 shares — an estimated $255K sold.

Quinn Opportunity Partners first reported a position in KROS in Q1 2025 and held it in 1 quarter. The position peaked at $255K in Q1 2025. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Quinn Opportunity Partners reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 25,000 Keros Therapeutics shares in Q2 2025, an estimated $255K.
  • Quinn Opportunity Partners first reported a position in Keros Therapeutics in Q1 2025 and held it in 1 quarter.
  • Quinn Opportunity Partners's Keros Therapeutics position peaked at $255K in Q1 2025.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Quinn Opportunity Partners's 13F filing for Q2 2025, filed 8 Aug 2025.